patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_648931 | REC_0007101 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 13.8 | 54 | female | 0 | 16 | 7.7 | 5 | pembrolizumab 200 mg q3w | 10.3 | false | MSS | 2026-03-15T05:35:58.594882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652421 | REC_0007102 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 7.9 | 81 | female | 2 | 21 | 6.2 | 2 | sotorasib 960 mg daily | 28.4 | false | MSS | 2026-03-15T05:35:58.595111+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_950240 | REC_0007103 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 6.9 | 70 | female | 2 | 25 | 5.2 | 2 | alectinib 600 mg BID | 24.6 | false | MSS | 2026-03-15T05:35:58.595341+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577473 | REC_0007104 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 15 | 77 | female | 1 | 4 | 4.6 | 2 | osimertinib 80 mg daily | 17.4 | false | MSS | 2026-03-15T05:35:58.595576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_317077 | REC_0007105 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7 | 70 | female | 2 | 21 | 6 | 5 | osimertinib 80 mg daily | 4.7 | true | MSS | 2026-03-15T05:35:58.595808+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475566 | REC_0007106 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 15.7 | 73 | female | 2 | 1 | 3.8 | 6 | osimertinib 80 mg daily | 10.2 | false | MSI-H | 2026-03-15T05:35:58.596036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830984 | REC_0007107 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 12.3 | 67 | female | 1 | 14 | 4 | 2 | entrectinib 600 mg daily | 19.6 | true | MSI-H | 2026-03-15T05:35:58.596370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876850 | REC_0007108 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 12.8 | 69 | female | 1 | 16 | 4.7 | 2 | osimertinib 80 mg daily | 16.6 | false | MSI-H | 2026-03-15T05:35:58.596605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895346 | REC_0007109 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.1 | 76 | female | 1 | 48 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.6 | false | MSS | 2026-03-15T05:35:58.596839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750223 | REC_0007110 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.9 | 88 | female | 2 | 9 | 5.8 | 2 | osimertinib 80 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:58.597072+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574078 | REC_0007111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 14.7 | 57 | male | 0 | 19 | 6.4 | 2 | entrectinib 600 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.597308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256996 | REC_0007112 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 8.8 | 73 | female | 2 | 15 | 4.1 | 2 | sotorasib 960 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.597585+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817249 | REC_0007113 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 13 | 62 | male | 0 | 19 | 6.4 | 2 | osimertinib 80 mg daily | 8.5 | true | MSI-H | 2026-03-15T05:35:58.597826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526518 | REC_0007114 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 16.5 | 59 | female | 0 | 25 | 4 | 1 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:58.598061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_946909 | REC_0007115 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.7 | 56 | female | 1 | 13 | 6.1 | 6 | entrectinib 600 mg daily | 15.1 | false | MSI-H | 2026-03-15T05:35:58.598293+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322936 | REC_0007116 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 29 | 12.3 | 60 | female | 1 | 18 | 4 | 8 | osimertinib 80 mg daily | 9.4 | true | MSI-H | 2026-03-15T05:35:58.598527+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182786 | REC_0007117 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 10.8 | 70 | female | 2 | 11 | 5.3 | 2 | osimertinib 80 mg daily | 21.2 | true | MSI-H | 2026-03-15T05:35:58.598759+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573819 | REC_0007118 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6.9 | 63 | male | 1 | 12 | 7.5 | 2 | sotorasib 960 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.598990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251726 | REC_0007119 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 4.2 | 65 | female | 0 | 12 | 5.1 | 1 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.599224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609037 | REC_0007120 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 3.5 | 75 | female | 2 | 36 | 3.6 | 7 | pembrolizumab 200 mg q3w | 11.8 | true | MSS | 2026-03-15T05:35:58.599451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587217 | REC_0007121 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 12 | 59 | female | 0 | 18 | 8.4 | 6 | entrectinib 600 mg daily | 17.4 | true | MSS | 2026-03-15T05:35:58.599687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762649 | REC_0007122 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 14.5 | 69 | female | 0 | 20 | 4.9 | 1 | osimertinib 80 mg daily | 28.3 | false | MSI-H | 2026-03-15T05:35:58.599916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_379170 | REC_0007123 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 9.9 | 56 | male | 1 | 18 | 6.3 | 2 | osimertinib 80 mg daily | 20.7 | false | MSS | 2026-03-15T05:35:58.600174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_276320 | REC_0007124 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 12 | 82 | female | 1 | 15 | 6.7 | 0 | alectinib 600 mg BID | 43.7 | false | MSI-H | 2026-03-15T05:35:58.600412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_858876 | REC_0007125 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 8.8 | 74 | female | 2 | 4 | 4.1 | 6 | pembrolizumab 200 mg q3w | 7.1 | false | MSS | 2026-03-15T05:35:58.600695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594079 | REC_0007126 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 9.5 | 70 | female | 3 | 13 | 5.2 | 1 | entrectinib 600 mg daily | 20 | true | MSS | 2026-03-15T05:35:58.600928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_202537 | REC_0007127 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 16.2 | 69 | female | 0 | 8 | 5.9 | 2 | osimertinib 80 mg daily | 25.3 | true | MSS | 2026-03-15T05:35:58.601162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_535226 | REC_0007128 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 14.2 | 74 | male | 2 | 12 | 6.5 | 2 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:35:58.601400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397800 | REC_0007129 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 14.2 | 70 | female | 0 | 16 | 6.4 | 6 | osimertinib 80 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:58.601635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_450199 | REC_0007130 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 8.9 | 74 | female | 3 | 0 | 8 | 5 | entrectinib 600 mg daily | 8 | false | MSS | 2026-03-15T05:35:58.601862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685059 | REC_0007131 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 13.4 | 63 | female | 1 | 20 | 5.7 | 4 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.602095+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350663 | REC_0007132 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 10 | 63 | female | 1 | 26 | 6 | 7 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:58.602331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115406 | REC_0007133 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.9 | 59 | female | 1 | 17 | 4.7 | 7 | sotorasib 960 mg daily | 10.9 | true | MSS | 2026-03-15T05:35:58.602560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_895893 | REC_0007134 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 34 | 17 | 68 | female | 1 | 6 | 6.8 | 0 | sotorasib 960 mg daily | 17.3 | false | MSI-H | 2026-03-15T05:35:58.602790+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300597 | REC_0007135 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.2 | 52 | female | 0 | 6 | 5.5 | 7 | osimertinib 80 mg daily | 14 | true | MSS | 2026-03-15T05:35:58.603022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_756827 | REC_0007136 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 8.1 | 64 | male | 0 | 14 | 6.8 | 4 | sotorasib 960 mg daily | 9.4 | true | MSS | 2026-03-15T05:35:58.603253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_111186 | REC_0007137 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 15.6 | 65 | male | 0 | 6 | 4.7 | 1 | osimertinib 80 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.603491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_984751 | REC_0007138 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.5 | 66 | female | 1 | 48 | 5.4 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.8 | false | MSS | 2026-03-15T05:35:58.603786+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900112 | REC_0007139 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 7 | 72 | female | 1 | 12 | 6.6 | 2 | sotorasib 960 mg daily | 14.9 | false | MSS | 2026-03-15T05:35:58.604026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406322 | REC_0007140 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.6 | 76 | female | 3 | 19 | 8.3 | 7 | osimertinib 80 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.604317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344717 | REC_0007141 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 4.1 | 73 | female | 1 | 13 | 4.4 | 3 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:58.604553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713388 | REC_0007142 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 2.9 | 67 | male | 1 | 26 | 6.7 | 1 | osimertinib 80 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:58.604785+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926971 | REC_0007143 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.4 | 64 | female | 1 | 20 | 4.7 | 2 | osimertinib 80 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:35:58.605025+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279060 | REC_0007144 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 14 | 16.5 | 64 | male | 0 | 13 | 5.6 | 5 | sotorasib 960 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:58.605262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755964 | REC_0007145 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 16 | 76 | male | 2 | 7 | 5 | 1 | osimertinib 80 mg daily | 12.7 | false | MSI-H | 2026-03-15T05:35:58.605499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_294883 | REC_0007146 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 27 | 16.7 | 77 | female | 1 | 19 | 9.4 | 0 | osimertinib 80 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:58.605729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_962998 | REC_0007147 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 12.5 | 61 | female | 1 | 12 | 6.3 | 5 | osimertinib 80 mg daily | 9.8 | false | MSI-H | 2026-03-15T05:35:58.605964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169177 | REC_0007148 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 4.1 | 65 | male | 1 | 48 | 7.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 14 | true | MSS | 2026-03-15T05:35:58.606195+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_322891 | REC_0007149 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 8.3 | 72 | female | 2 | 18 | 6.5 | 9 | sotorasib 960 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:58.606422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672703 | REC_0007150 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 8.2 | 72 | male | 1 | 18 | 4.5 | 1 | sotorasib 960 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:58.606657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610910 | REC_0007151 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8.4 | 76 | male | 2 | 10 | 6 | 5 | alectinib 600 mg BID | 13.4 | true | MSS | 2026-03-15T05:35:58.606939+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_147502 | REC_0007152 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 9.4 | 71 | female | 1 | 15 | 7 | 1 | sotorasib 960 mg daily | 26.4 | false | MSS | 2026-03-15T05:35:58.607171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_588485 | REC_0007153 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 18 | 10.8 | 63 | female | 1 | 23 | 2.3 | 1 | sotorasib 960 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.607404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_922703 | REC_0007154 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 14 | 4.3 | 60 | male | 1 | 42 | 4.6 | 3 | carboplatin + paclitaxel + pembrolizumab | 12.5 | true | MSS | 2026-03-15T05:35:58.607636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965189 | REC_0007155 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 8.8 | 62 | male | 1 | 21 | 4.5 | 1 | osimertinib 80 mg daily | 18.5 | true | MSS | 2026-03-15T05:35:58.607867+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_507105 | REC_0007156 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 16.1 | 75 | female | 2 | 10 | 5 | 5 | pembrolizumab 200 mg q3w | 4 | false | MSS | 2026-03-15T05:35:58.608129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994621 | REC_0007157 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.1 | 60 | male | 0 | 22 | 4 | 5 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.608366+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423181 | REC_0007158 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 10.6 | 66 | male | 1 | 11 | 4.2 | 2 | osimertinib 80 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:58.608602+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_500514 | REC_0007159 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 19 | 53 | female | 0 | 13 | 6.9 | 2 | entrectinib 600 mg daily | 19 | false | MSI-H | 2026-03-15T05:35:58.608838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692353 | REC_0007160 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.3 | 71 | male | 4 | 0 | 4.2 | 5 | sotorasib 960 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:58.609067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262665 | REC_0007161 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.6 | 75 | female | 2 | 7 | 6.1 | 4 | alectinib 600 mg BID | 14.7 | true | MSS | 2026-03-15T05:35:58.609298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_874738 | REC_0007162 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 7 | 64 | male | 0 | 71 | 5.3 | 1 | pembrolizumab 200 mg q3w | 20.2 | true | MSS | 2026-03-15T05:35:58.609529+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204134 | REC_0007163 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.6 | 73 | female | 1 | 76 | 6.6 | 1 | pembrolizumab 200 mg q3w | 19.3 | true | MSS | 2026-03-15T05:35:58.609757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385110 | REC_0007164 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 7 | 77 | male | 0 | 17 | 5.5 | 6 | osimertinib 80 mg daily | 5.5 | true | MSS | 2026-03-15T05:35:58.610035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783575 | REC_0007165 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 14.4 | 67 | female | 1 | 8 | 5.4 | 4 | entrectinib 600 mg daily | 8.4 | false | MSI-H | 2026-03-15T05:35:58.610275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646134 | REC_0007166 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 2.2 | 57 | female | 1 | 17 | 5.7 | 4 | osimertinib 80 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:58.610510+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_159660 | REC_0007167 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 16.7 | 66 | female | 0 | 20 | 6 | 6 | osimertinib 80 mg daily | 4.4 | false | MSI-H | 2026-03-15T05:35:58.610750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_740651 | REC_0007168 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 14.2 | 82 | female | 2 | 23 | 5.9 | 2 | osimertinib 80 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.610979+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951645 | REC_0007169 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 16.1 | 60 | male | 2 | 19 | 4.3 | 4 | sotorasib 960 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.611216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483050 | REC_0007170 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 5.6 | 77 | female | 1 | 27 | 3.5 | 5 | osimertinib 80 mg daily | 10.8 | true | MSS | 2026-03-15T05:35:58.611447+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_960120 | REC_0007171 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 21.8 | 56 | male | 1 | 14 | 6.6 | 1 | sotorasib 960 mg daily | 16.9 | false | MSI-H | 2026-03-15T05:35:58.611683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_583421 | REC_0007172 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 14 | 84 | female | 1 | 23 | 4.6 | 1 | osimertinib 80 mg daily | 17.2 | false | MSS | 2026-03-15T05:35:58.611920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_717145 | REC_0007173 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 15.2 | 51 | female | 0 | 15 | 5.4 | 1 | alectinib 600 mg BID | 18.2 | false | MSI-H | 2026-03-15T05:35:58.612207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_996648 | REC_0007174 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.1 | 58 | female | 0 | 24 | 6.6 | 7 | pembrolizumab 200 mg q3w | 9.5 | false | MSS | 2026-03-15T05:35:58.612448+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460686 | REC_0007175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 8.2 | 73 | female | 1 | 25 | 4.2 | 3 | alectinib 600 mg BID | 12.2 | true | MSS | 2026-03-15T05:35:58.612677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263639 | REC_0007176 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 10.9 | 76 | male | 2 | 4 | 4.6 | 4 | osimertinib 80 mg daily | 11.7 | false | MSI-H | 2026-03-15T05:35:58.612913+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_127899 | REC_0007177 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.6 | 77 | female | 2 | 20 | 6.3 | 5 | alectinib 600 mg BID | 14.3 | true | MSS | 2026-03-15T05:35:58.613188+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543224 | REC_0007178 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 14 | 7.1 | 75 | female | 0 | 12 | 2.2 | 10 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:58.613423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321317 | REC_0007179 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.2 | 64 | male | 0 | 18 | 6 | 6 | entrectinib 600 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:58.613659+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319635 | REC_0007180 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 6.6 | 66 | female | 0 | 18 | 6.8 | 0 | osimertinib 80 mg daily | 36.7 | false | MSS | 2026-03-15T05:35:58.613885+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_254404 | REC_0007181 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 13.2 | 84 | male | 3 | 14 | 5 | 1 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.614120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_956327 | REC_0007182 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 6 | 69 | female | 1 | 21 | 7.2 | 6 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.614345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198454 | REC_0007183 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.5 | 45 | female | 0 | 25 | 5 | 7 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:58.614579+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_133185 | REC_0007184 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.2 | 57 | male | 1 | 7 | 4.3 | 2 | osimertinib 80 mg daily | 17.6 | true | MSS | 2026-03-15T05:35:58.614811+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819111 | REC_0007185 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 18 | 60 | male | 1 | 19 | 6.1 | 3 | entrectinib 600 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.615045+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_638068 | REC_0007186 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.2 | 70 | male | 3 | 0 | 7.4 | 7 | alectinib 600 mg BID | 14.3 | false | MSS | 2026-03-15T05:35:58.615278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169909 | REC_0007187 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 6.9 | 71 | female | 2 | 15 | 6.8 | 1 | entrectinib 600 mg daily | 31.9 | false | MSS | 2026-03-15T05:35:58.615506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788014 | REC_0007188 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.2 | 73 | female | 1 | 66 | 7.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 34.8 | true | MSS | 2026-03-15T05:35:58.615732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739376 | REC_0007189 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 4.8 | 66 | female | 1 | 17 | 5 | 4 | osimertinib 80 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:58.615960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845880 | REC_0007190 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 14.3 | 61 | male | 0 | 19 | 7.5 | 7 | entrectinib 600 mg daily | 11.9 | false | MSS | 2026-03-15T05:35:58.616466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_975347 | REC_0007191 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 16.8 | 44 | male | 0 | 16 | 3.7 | 0 | entrectinib 600 mg daily | 10.4 | true | MSI-H | 2026-03-15T05:35:58.616718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_212655 | REC_0007192 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.5 | 86 | female | 1 | 54 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:58.616960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_801680 | REC_0007193 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 10.1 | 83 | female | 2 | 17 | 5.7 | 2 | sotorasib 960 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:35:58.617196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909693 | REC_0007194 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 6.3 | 60 | female | 0 | 21 | 5.6 | 7 | alectinib 600 mg BID | 9.1 | true | MSS | 2026-03-15T05:35:58.617428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915624 | REC_0007195 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 6.2 | 63 | female | 0 | 14 | 7.7 | 1 | alectinib 600 mg BID | 20.6 | false | MSS | 2026-03-15T05:35:58.617660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794696 | REC_0007196 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 7.6 | 63 | female | 1 | 5 | 6.4 | 2 | sotorasib 960 mg daily | 16 | true | MSS | 2026-03-15T05:35:58.617890+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229950 | REC_0007197 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.3 | 72 | male | 0 | 15 | 4.4 | 7 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:58.618120+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309339 | REC_0007198 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 34 | 3.9 | 62 | male | 0 | 6 | 3.6 | 1 | pembrolizumab 200 mg q3w | 21 | false | MSS | 2026-03-15T05:35:58.618353+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935426 | REC_0007199 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 13 | 71 | female | 2 | 20 | 6.9 | 5 | entrectinib 600 mg daily | 12.1 | true | MSS | 2026-03-15T05:35:58.618589+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_416133 | REC_0007200 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 2.9 | 84 | female | 2 | 11 | 5.6 | 2 | osimertinib 80 mg daily | 19.1 | true | MSS | 2026-03-15T05:35:58.618818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.